NeoGenomics announced that its PanTracer LBx, a blood-based comprehensive genomic profiling test for advanced solid tumors, received CMS coverage. The decision covers the assay for therapy selection and clinical trial enrollment, potentially broadening access to liquid biopsy-guided precision oncology. NeoGenomics said the coverage supports integration of the test into clinical workflows and could drive increased adoption for patients unable to obtain tissue biopsies. The move aligns payer policy with the growing clinical role of blood-based CGP.